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A B S T R A C T
DiGeorge syndrome – a component of the 22q11 deletion syndrome – causes a disturbance in cervical
neural crest migration that results in parathyroid hypoplasia. Patients can develop hypocalcemia-
induced seizures. Spina biﬁda is caused by failure of neurulation, including a disturbance in the adhesion
processes at the neurula stage. Spina biﬁda has been reported as a risk factor for epilepsy.
We report, for the ﬁrst time, the case of a patientwith DiGeorge syndromewith spina biﬁda and sacral
myelomeningocele, who developed both hypocalcemia-induced seizures and epilepsy. The patient had
spina biﬁda and sacral myelomeningocele at birth. At the age of 13 years, he experienced a seizure for the
ﬁrst time. At this time, the calcium concentration was normal. An electroencephalogram (EEG) proved
that the seizure was due to epilepsy. Antiepileptic medications controlled the seizure. At the age of 29,
the patient’s calcium concentration began to reduce. At the age of 40, hypocalcemia-induced seizure
occurred. At this time, the calcium concentration was 5.5 mg/dL (reference range, 8.7–10.1 mg/dL). The
level of intact parathyroid hormone (PTH) was 6 pg/mL (reference range, 10–65 pg/mL). Chromosomal
and genetic examinations revealed a deletion of TUP-like enhancer of split gene 1 (tuple1)—the
diagnostic marker of DiGeorge syndrome. Many patients with DiGeorge syndrome have cardiac
anomalies; however, our patient had none.
We propose that the association among DiGeorge syndrome, spina biﬁda, epilepsy, cardiac anomaly,
22q11, tuple1, and microdeletion inheritance should be clariﬁed for appropriate diagnosis and treatment.
 2010 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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DiGeorge syndrome (Online Mendelian Inheritance in Man
(OMIM), #188400) is a congenital disorder that ismainly caused by
deletion of chromosome 22q11.2. Patients can exhibit various
anomalies, such as parathyroid hypoplasia, thymic hypoplasia, and
cardiac outﬂow tract defects, due to a disturbance in cervical
neural crest migration into the derivatives of the pharyngeal
arches and pouches.1 Patients with DiGeorge syndrome can
develop hypocalcemia-induced seizure due to parathyroid hypo-
plasia. Spina biﬁda is caused by failure of neurulation, including a
disturbance in the adhesion processes at the neurula stage.2 Spina
biﬁda has been reported as a risk factor for epilepsy.3 There have* Corresponding author. Tel.: +81 3 3633 6151; fax: +81 3 3633 6173.
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doi:10.1016/j.seizure.2010.04.005been some case reports of DiGeorge syndrome with spina biﬁda
and subsequent meningocele or myelomeningocele.4–7 However,
spina biﬁda has not been described as a complication of DiGeorge
syndrome in standard textbooks of pediatrics8 or endocrinology,9
though both developed neural migration and adhesion distur-
bance.
Here, we report the case of a patient with DiGeorge syndrome
with spina biﬁda and sacral myelomeningocele, who developed
both hypocalcemia-induced seizures and epilepsy. We discuss the
possible association between these anomalies and their symptoms.
1.1. Case report
The patient was male and was born with spina biﬁda and sacral
myelomeningocele in Japan in 1969. At the age of 7 months, he
underwent surgery for sacral myelomeningocele. In 1982, at the
age of 13 years, he experienced a seizure for the ﬁrst time. At thisvier Ltd. All rights reserved.
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logram (EEG) examination, the seizure was found to be caused by
epilepsy. Antiepileptic medications controlled the seizure. In 1998,
at the age of 29, the patient’s calcium concentration began to
reduce and dropped to 8.3 mg/dL (reference range, 8.7–10.1 mg/
dL). In 2005, at the age of 36, this concentration reduced to 7.1 mg/
dL. In 2009, at the age of 40, the patient began to experience
seizures approximately once a month. In August 2009, he visited
the emergency department of our hospital because he experienced
generalized seizure. At this time, his calcium concentration was
5.5 mg/dL. The level of intact parathyroid hormone (PTH)was 6 pg/
mL (reference range, 10–65 pg/mL). The parathyroid glands were
not detected on neck echograms and enhanced computed
tomography (CT) scans. Chromosomal and genetic examinations
revealed a deletion of TUP-like enhancer of split gene 1 (tuple1).
Tuple1 is a putative transcriptional regulator isolated from
DiGeorge syndrome critical region on the human chromosome
22q1110 and is a diagnostic marker of DiGeorge syndrome.11 On
the basis of these results, we established the diagnosis of DiGeorge
syndrome. On treatment with the active form of vitamin D at a
dose of 2mg/day, the patient’s calcium concentration was
normalized and the seizures disappeared.
At the age of 40, the patient had severe mental retardation.
Head CT did not reveal enlargement of the cerebral ventricles or
any other anomalies. The patient’s height was 146 cm and his
weight, 66.0 kg; thus, his body mass index (BMI) was 31.0 kg/m2.
The face had the typical appearance associated with DiGeorge
syndrome; low-set ears and telecanthus. The thyroid gland could
not be seen on neck echograms and enhanced CT scans, though the
thyroid hormones were within normal limits. He had repeatedly
suffered from respiratory and urinary tract infections since birth.
Systemic skin candidiasis was also observed. No cardiac anomalies
were detected by cardiac echography and enhanced CT. The plasma
concentration of brain natriuretic peptide (BNP) was 5.8 pg/mL
(reference range, 0.0–18.4 pg/mL). CT revealed sacral spina biﬁda.
The patient also had a progressive urethral ﬁssure and stricture. He
had no family history of facial abnormalities, repeated infection,
seizures, or cardiac anomalies. His mother was not an alcoholic
when she was pregnant with him.
2. Discussion
Here, we report, for the ﬁrst time, the case of a patient with
DiGeorge syndrome with spina biﬁda and sacral myelomeningo-
cele, who developed both hypocalcemia-induced seizures and
epilepsy.
DiGeorge syndrome is a component of the chromosome
22q11.2 deletion syndrome and the most common microdeletion
syndrome in humans, with an incidence of 1 in 4000.12 The
chromosome 22q11.2 deletion syndrome includes DiGeorge
syndrome, velocardiofacial syndrome, and CATCH-22 syndrome
(cardiac defects, abnormal facies, thymic hypoplasia, cleft palate,
and hypocalcemia).1 Therefore, patients with DiGeorge syndrome
can present various features.
Neural tube defects, including spina biﬁda, have amultifactorial
etiology encompassing both genetic and environmental compo-
nents. With a birth incidence of approximately 1 in 1000, these
defects are the second most common type of birth defects after
congenital heart defects.13 Neural tube defects are of 2 types: (a)
spina biﬁda occulta – a bony defect of the spine covered by normal
skin – is a mild form of spina biﬁda and is often asymptomatic, and
(b) open spina biﬁda – also known as spina biﬁda cystica or
myelomeningocele – is a severe form and often accompanies
anencephaly or Arnold-Chiari malformation.13
There have been some case reports of DiGeorge syndrome with
spina biﬁda and subsequent meningocele or myelomeningocele.4–7 Nickel reported cases of 3 unrelated patients with chromosome
22q11 deletion syndromes—2 with velocardiofacial syndrome and
1 with DiGeorge syndrome—who had neural tube defects.7 This
author recommended that for all children with neural tube defects
and congenital heart defects, cytogenetic and molecular studies
should be performed to detect chromosome 22q11 deletions.
However, in a follow-up study of 295 patients with spina biﬁda,
Nickel andMagenis concluded that 22q11 deletion is an infrequent
cause of neural tube defects.14 Nevertheless, to the best of our
knowledge, this study byNickel andMagenis has been the only one
to examine the association between neural tube defects and 22q11.
Another study may reveal a positive association between neural
tube defects and the DiGeorge syndrome, since both developed
neural migration and adhesion disturbance.
There have been some studies on spina biﬁda and epilepsy.
Okuroeska studied the cases of 86 patients with myelomeningo-
cele: a standard EEG obtained in the waking state revealed that 53
patients (62%) showed generalized changes—19 (79%) had thoracic
myelomeningocele; 28 (53%), lumbar myelomenigocele; and 6
(66%), sacral myelomeningocele.3 Clinical practitioners should be
aware of the association betweenmyelomeningocele and epilepsy.
However, Yoshida et al. reported no association between
myelomeningocele and epilepsy; they found only myeloschisis –
the most severe neural tube defect – to be associated with
epilepsy.15 The association between spina biﬁda and epilepsy
should be further explored. Gonza´lez and Bautista reported that
patientswith DiGeorge syndromewithout spina biﬁda can develop
epilepsy with abnormalities on an EEG.16 Thus, clinical practi-
tioners should also be aware of the association between DiGeorge
syndrome itself and epilepsy.
Neonatal hypocalcemia due to parathyroid hypoplasia is one of
the primary features of DiGeorge syndrome.8 However, in our
patient, hypocalcemia was late onset, and there have been another
reports of late onset hypocalcemia in DiGeorge syndrome.17,18 The
neonatal hypocalcaemia in DiGeorge syndrome generally
improves over the 1st year of life as the parathyroid glands
hypertrophy. Therefore, for those who survive, few older patients
require ongoing calcium supplementation.17 We infer that
hypocalcemia become evident when hypertrophy cannot com-
pensate hypoplasia.
In Japan, the cardiovascular manifestations of DiGeorge
syndrome, especially tetralogy of Fallot, have received particular
attention,1 and there have been several reports regarding
associated cardiovascular anomalies.19–21 Roberts et al. reported
that in humans and mice, the tuple1 gene is expressed at a critical
point during the development of the cardiac outﬂow tract and the
neural crest.22 Lu et al. identiﬁed 22q11 deletion in 14 of 84 (16.7%)
patients with sporadic tetralogy of Fallot, and tuple1 deletion in 13
of these 14 (92.9%) patients with 22q11 deletion.23 Choi et al.
reported that 44 of 61 (72.1%) patients with tuple1 deletion exhibit
congenital heart defects.24 However, although our patient was
Japanese and had tuple1 deletion, he did not exhibit any cardiac
anomalies. Maternal inheritance of 22q11 microdeletion has been
reported as a risk factor for tetralogy of Fallot.25,26 Therefore, in our
patient, the 22q11deletion may have been paternally inherited or
occurred sporadically. Further studies should be performed to
determine the association among 22q11, the tuple1 gene, and
cardiac anomalies.
In conclusion, we propose that the association among DiGeorge
syndrome, spina biﬁda, epilepsy, cardiac anomalies, 22q11, tuple1,
and microdeletion inheritance should be clariﬁed for appropriate
diagnosis and treatment of DiGeorge syndrome.
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